The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
A Double-Blind, Randomized Study of Minocycline for the Treatment of Negative and Cognitive Symptoms in Early-Phase Schizophrenia
Abstract
BACKGROUND: Current antipsychotics have only a limited effect on 2 core aspects of schizophrenia: negative symptoms and cognitive deficits. Minocycline is a second-generation tetracycline that has a beneficial effect in various neurologic disorders. Recent findings in animal models and human case reports suggest its potential for the treatment of schizophrenia. These findings may be linked to the effect of minocycline on the glutamatergic system, through inhibition of nitric oxide synthase and blocking of nitric oxide-induced neurotoxicity. Other proposed mechanisms of action include effects of minocycline on the dopaminergic system and its inhibition of microglial activation. OBJECTIVE: To examine the efficacy of minocycline as an add-on treatment for alleviating negative and cognitive symptoms in early-phase schizophrenia. METHOD: A longitudinal double-blind, randomized, placebo-controlled design was used, and patients were followed for 6 months from August 2003 to March 2007. Seventy early-phase schizophrenia patients (according to DSM-IV) were recruited and 54 were randomly allocated in a 2:1 ratio to minocycline 200 mg/d. All patients had been initiated on treatment with an atypical antipsychotic < or = 14 days prior to study entry (risperidone, olanzapine, quetiapine, or clozapine; 200-600 mg/d chlorpromazine-equivalent doses). Clinical, cognitive, and functional assessments were conducted, with the Scale for the Assessment of Negative Symptoms (SANS) as the primary outcome measure. RESULTS: Minocycline was well tolerated, with few adverse events. It showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale). A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning). CONCLUSIONS: Minocycline treatment was associated with improvement in negative symptoms and executive functioning, both related to frontal-lobe activity. Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00733057.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Various clinical trials have been conducted using minocycline alone or as an adjunct to risperidone in patients with schizophrenia and have demonstrated overall improvement in negative symptoms and executive functioning (Miyaoka et al., 2008; Levkovitz et al., 2010; Khodaie-Ardakani et al., 2014).”
From The Perineuronal ‘Safety’ Net? Perineuronal Net Abnormalities in Neurological Disorders (2018) · cites this paper as Levkovitz et al., 2010
In the citing paper
“The sole exception was a trial29 that assessed the effects of a 6-month add-on treatment with either minocycline or placebo on cognitive impairment in young subjects in early phase schizophrenia, aged 18–35 years.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Minocycline showed a beneficial effect on negative symptoms and general outcome (evident in SANS, Clinical Global Impressions scale).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• Overall, the findings support the beneficial effect of minocycline add-on therapy in early-phase schizophrenia.”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“• A similar pattern was found for cognitive functioning, mainly in executive functions (working memory, cognitive shifting, and cognitive planning).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“A trial performed in younger subjects with recent illness onset29 may yield more positive results than those conducted in patients with an average illness duration of >20 years (See table 1).”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“In this study, minocycline, a tetracycline antibiotic with a distinct neuroprotective profile, was found to be significantly superior to placebo at endpoint in improving cognitive functioning as well as negative symptoms and general outcome.29”
From Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? (2013) · cites this paper as [29]
In the citing paper
“add-on administration of minocycline for 22 weeks was associated with improvements in executive functions in individuals with early-phase schizophrenia [107].”
From Cognitive remission: a novel objective for the treatment of major depression? (2016) · cites this paper as [107]
Citations
Cites
Maximum Likelihood from Incomplete Data Via the EM Algorithm
Dempster, A. P., Laird, N. M., & Rubin, D. B. (1977) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1977.tb01600.x · Cited by 50,444
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378
Miyake, A., Friedman, N. P., Emerson, M. J., Witzki, A. H., Howerter, A., & Wager, T. D. (2000) · Cognitive Psychology · doi:10.1006/cogp.1999.0734 · Cited by 15,798
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
The Global Assessment Scale: A Procedure for Measuring Overall Severity of Psychiatric Disturbance
Endicott, J. (1976) · Archives of General Psychiatry · doi:10.1001/archpsyc.1976.01770060086012 · Cited by 4,982
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Physiologic Dysfunction of Dorsolateral Prefrontal Cortex in Schizophrenia
Weinberger, D. R. (1986) · Archives of General Psychiatry · doi:10.1001/archpsyc.1986.01800020020004 · Cited by 2,025
Negative v Positive Schizophrenia
Andreasen, N. C. (1982) · Archives of General Psychiatry · doi:10.1001/archpsyc.1982.04290070025006 · Cited by 2,008
Executive Function and the Frontal Lobes: A Meta-Analytic Review
Alvarez, J. A., & Emory, E. (2006) · Neuropsychology Review · doi:10.1007/s11065-006-9002-x · Cited by 1,981
Cited by
Sorted by citations
Items 201–300 of 390
The search for new biomarkers for cognition in schizophrenia
Penadés, R., García‐Rizo, C., Bioque, M., González-Rodríguez, A., Cabrera, B., Mezquida, G., & Bernardo, M. (2015) · Schizophrenia Research Cognition · doi:10.1016/j.scog.2015.10.004 · Cited by 34
Anti-inflammatory effects of minocycline are mediated by retinoid signaling
Clemens, V., Regen, F., Bret, N. L., Heuser, I., & Hellmann‐Regen, J. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0460-x · Cited by 34
You, M., Bang, M., Park, H., Yang, B., Jang, K. B., Yoo, J., Hwang, D., Kim, M., Kim, B., Lee, S., et al. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0802-1 · Cited by 33
An Update on Treatment of Cognitive Impairment Associated with Schizophrenia
Horan, W. P., Catalano, L. T., & Green, M. F. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_382 · Cited by 31
Antipsychotics and Physical Attractiveness
Seeman, M. (2011) · Clinical Schizophrenia & Related Psychoses · doi:10.3371/csrp.5.3.4 · Cited by 31
Michalopoulou, P. G., Lewis, S. W., Wykes, T., Jaeger, J., & Kapur, S. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.03.012 · Cited by 30
Nettis, M. A. (2021) · Brain Behavior & Immunity - Health · doi:10.1016/j.bbih.2021.100335 · Cited by 32
Minocycline effect on life and health span of Drosophila melanogaster.
Oxenkrug, G. F., Navrotskaya, V., Vorobyova, L., & D, P. S. M. (2012) · Europe PMC (PubMed Central) · Cited by 29
Zhu, F., Liu, Y., Zhao, J., & Zheng, Y. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.01.021 · Cited by 29
Ardakani, M. R. K., Seddighi, S., Modabbernia, A., Rezaei, F., Salehi, B., Ashrafi, M., Shams‐Alizadeh, N., Mohammad-karimi, M., Esfandiari, G.-R., Hajiaghaee, R., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.01.011 · Cited by 29
Are CB2 Receptors a New Target for Schizophrenia Treatment?
Cortez, I. L., da Silva, N. R., Guimarães, F. S., & Gomes, F. V. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.587154 · Cited by 29
Ioannou, M., Foiselle, M., Mallet, J., Stam, E. L., Godin, O., Dubertret, C., Terro, E., Sommer, I. E., Haarman, B. C. M., Leboyer, M., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.11.001 · Cited by 28
Zeinoddini, A., Ahadi, M., Farokhnia, M., Rezaei, F., Tabrizi, M. H., & Akhondzadeh, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.08.016 · Cited by 27
Keeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27
Microglial regulation of satiety and cognition
Luca, S. N. D., Miller, A. A., Sominsky, L., & Spencer, S. J. (2020) · Journal of Neuroendocrinology · doi:10.1111/jne.12838 · Cited by 28
Seitz‐Holland, J., Seethaler, M., Makris, N., Rushmore, J., Cho, K.-I. K., Rizzoni, E., Vangel, M. G., Şenay, O., Heller, C., Pasternak, O., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-021-00997-5 · Cited by 28
Inflammatory neuropsychiatric disorders and COVID-19 neuroinflammation
Tang, S. W., Helmeste, D. M., & Leonard, B. E. (2021) · Acta Neuropsychiatrica · doi:10.1017/neu.2021.13 · Cited by 27
Baek, S.-H., Kim, H., Kim, J., Ryu, S., Lee, J., Kim, J., Shin, I., & Kim, S. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12071137 · Cited by 31
Kato, T. A., Watabe, M., & Kanba, S. (2013) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2013.00139 · Cited by 29
Prandota, J. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000241 · Cited by 29
Newer antipsychotics and upcoming molecules for schizophrenia
George, M., Amrutheshwar, R., Rajkumar, R. P., Kattimani, S., & Dkhar, S. A. (2013) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1498-4 · Cited by 26
Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia
GOFF, D. C. (2013) · World Psychiatry · doi:10.1002/wps.20026 · Cited by 25
Govil, P., & Kantrowitz, J. T. (2025) · CNS Drugs · doi:10.1007/s40263-024-01151-7 · Cited by 31
Obregon, D. F., Parker-Athill, E. C., Tan, J., & Murphy, T. K. (2012) · Neuropsychiatry · doi:10.2217/npy.12.41 · Cited by 25
Wass, C., Klamer, D., Katsarogiannis, E., Pålsson, E., Svensson, L., Fejgin, K., Bogren, I.-B., Engel, J. A., & Rembeck, B. (2011) · BMC Medicine · doi:10.1186/1741-7015-9-40 · Cited by 25
Potential Role of Oestrogen Modulation in the Treatment of Neurocognitive Deficits in Schizophrenia
Weickert, T. W., Allen, K. M., & Weickert, C. S. (2016) · CNS Drugs · doi:10.1007/s40263-016-0312-0 · Cited by 25
Glial pathology in neuropsychiatric disorders: a brief review
Mayegowda, S. B., & Thomas, C. (2019) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2018-0120 · Cited by 25
Adjunctive Raloxifene and Isradipine Improve Cognitive Functioning in Patients With Schizophrenia
Vahdani, B., Kian, A. A., Esmaeilzadeh, A., Zenoozian, S., Yousefi, V., & Mazloomzadeh, S. (2020) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001274 · Cited by 24
Epigenetic Alterations of Brain Non-Neuronal Cells in Major Mental Diseases
Abdolmaleky, H. M., Martin, M., Zhou, J., & Thiagalingam, S. (2023) · Genes · doi:10.3390/genes14040896 · Cited by 23
Levkovitch-Verbin, H., Spierer, O., Vander, S., & Dardik, R. (2011) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-010-1608-2 · Cited by 25
Self-citationNeuroprogression in Schizophrenia and Psychotic Disorders: The Possible Role of Inflammation
Müller, N. (2017) · Modern trends in psychiatry · doi:10.1159/000470802 · Cited by 27
Ganguly, K., Adhikary, K., Acharjee, A., Acharjee, P., Trigun, S. K., Mutlaq, A. S., Ashique, S., Yasmin, S., Alshahrani, A. M., & Ansari, M. Y. (2024) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2024.135967 · Cited by 23
Alternative pharmacologic targets for the treatment of schizophrenia
Miyamoto, S., Jarskog, L. F., & Fleischhacker, W. W. (2013) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32835d8296 · Cited by 23
Strawbridge, R., Carter, R., Saldarini, F., Tsapekos, D., & Young, A. H. (2021) · BJPsych Open · doi:10.1192/bjo.2021.966 · Cited by 23
Fathian, F., Løberg, E., Gjestad, R., Steen, V. M., Kroken, R. A., Jørgensen, H. A., & Johnsen, E. (2018) · Acta Neuropsychiatrica · doi:10.1017/neu.2018.25 · Cited by 24
Huang, H., Luo, Z., Min, J., Luo, W., Zhou, X., & Wang, C. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114910 · Cited by 25
Prenatal and Childhood Immuno-Metabolic Risk Factors for Adult Depression and Psychosis
Kappelmann, N., Perry, B. I., & Khandaker, G. M. (2022) · Harvard Review of Psychiatry · doi:10.1097/hrp.0000000000000322 · Cited by 22
Nagano, T., Mizuno, M., Morita, K., & Nawa, H. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_399 · Cited by 21
Romero‐Miguel, D., Casquero‐Veiga, M., MacDowell, K. S., Torres-Sánchez, S., Garcia-Partida, J. A., Lamanna‐Rama, N., Romero‐Miranda, A., Berrocoso, E., Leza, J. C., Desco, M., et al. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab036 · Cited by 21
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia
Li, M., Qiu, Y., Zhang, J., Zhang, Y., Liu, Y., Zhao, Y., Jia, Q., Fan, X., & Li, J. (2022) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-021-01359-4 · Cited by 21
Biomarkers in Psychosis: An Approach to Early Identification and Individualized Treatment
Mirzakhanian, H., Singh, F., & Cadenhead, K. S. (2013) · Biomarkers in Medicine · doi:10.2217/bmm.13.134 · Cited by 21
Buonaguro, E. F., Tomasetti, C., Chiodini, P., Marmo, F., Latte, G., Rossi, R., Avvisati, L., Iasevoli, F., & de Bartolomeis, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658987 · Cited by 21
Brain in flames – animal models of psychosis: utility and limitations
Wolf, S. A., Mattei, D., & Schweibold, R. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s65564 · Cited by 24
Immunomodulatory Effects of Clozapine: More Than Just a Side Effect in Schizophrenia
Amerio, A., Magnani, L., Arduino, G., Fesce, F., de Filippis, R., Parise, A., Costanza, A., Nguyen, K. D., Saverino, D., Berardis, D. D., et al. (2023) · Current Neuropharmacology · doi:10.2174/1570159x22666231128101725 · Cited by 21
Cortical gray matter loss in schizophrenia: Could microglia be the culprit?
Rački, V., Petrić, D., Kučić, N., Gržeta, N., Jurdana, K., & Rončević-Gržeta, I. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2015.12.021 · Cited by 22
Hamidkhaniha, S., Bashiri, H., Omidi, A., Hosseini‐Chegeni, A., Tavangar, S. M., Sabouri, S., Montazeri, H., & Sahebgharani, M. (2019) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.13090 · Cited by 20
Chan, S. Y., Capitão, L. P., Probert, F., Klinge, C., Höckner, S., Harmer, C. J., Cowen, P. J., Anthony, D. C., & Burnet, P. W. J. (2020) · Translational Psychiatry · doi:10.1038/s41398-020-0818-6 · Cited by 19
Human iPSC-Derived Glia as a Tool for Neuropsychiatric Research and Drug Development
Heider, J., Vogel, S., Volkmer, H., & Breitmeyer, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910254 · Cited by 23
Ahmed, A. O., & Bhat, I. (2014) · CNS Drugs · doi:10.1007/s40263-014-0146-6 · Cited by 20
Pharmacotherapy of cognitive deficits in schizophrenia
Opler, L. A., Medalia, A. A., Opler, M. G., & Stahl, S. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000771 · Cited by 20
Fekadu, A., Mesfin, M., Medhin, G., Alem, A., Teferra, S., Gebre-Eyesus, T., Seboxa, T., Assefa, A., Hussein, J., Lemma, M. T., et al. (2013) · Trials · doi:10.1186/1745-6215-14-406 · Cited by 19
Francis, M., Hummer, T. A., Liffick, E., Vohs, J. L., Mehdiyoun, N. F., Visco, A. C., Yang, Z., Kovacs, R. J., Zhang, Y., & Breier, A. F. (2020) · Brain Imaging and Behavior · doi:10.1007/s11682-020-00375-7 · Cited by 17
Minocycline as a prospective therapeutic agent for cancer and non-cancer diseases: a scoping review
Rezaei, A., Moqadami, A., & Khalaj‐Kondori, M. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02839-1 · Cited by 18
Poggini, S., Banqueri, M., Albanese, N. C., Golia, M. T., Ibáñez, F. G., Limatola, C., Fuhrmann, M., Lalowski, M. M., Tremblay, M., Maggi, L., et al. (2022) · Behavioural Brain Research · doi:10.1016/j.bbr.2023.114295 · Cited by 18
Early Life Stress, Neuroinflammation, and Psychiatric Illness of Adulthood
Shin, S. H., & Kim, Y. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_6 · Cited by 19
Inhibition of brain retinoic acid catabolism: a mechanism for minocycline's pleiotropic actions?
Regen, F., Bret, N. L., Hildebrand, M., Herzog, I., Heuser, I., & Hellmann‐Regen, J. (2015) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2015.1036116 · Cited by 20
Minocycline, a microglial inhibitor, reduces ‘honey trap’ risk in human economic exchange
Watabe, M., Kato, T. A., Tsuboi, S., Ishikawa, K., Hashiya, K., Monji, A., Utsumi, H., & Kanba, S. (2013) · Scientific Reports · doi:10.1038/srep01685 · Cited by 18
Rhee, H., & Cameron, D. J. (2012) · International Journal of General Medicine · doi:10.2147/ijgm.s24212 · Cited by 16
Li, S., Sakurai, K., Ohgidani, M., Kato, T. A., & Hikida, T. (2023) · Molecular Brain · doi:10.1186/s13041-023-01047-5 · Cited by 16
Wang, D., Chen, D., Xiu, M., Wang, L., Kosten, T. R., & Zhang, X. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01760-8 · Cited by 15
Investigation of TSPO Variants in Schizophrenia and Antipsychotic Treatment Outcomes
Pouget, J. G., Gonçalves, V. F., Nurmi, E. L., Laughlin, C., Mallya, K. S., McCracken, J. T., Aman, M. G., McDougle, C. J., Scahill, L. D., Misener, V. L., et al. (2015) · Pharmacogenomics · doi:10.2217/pgs.14.158 · Cited by 16
Antipsychotic-like effect of minocycline in a rat model.
Dokuyucu, R., Kokaçya, M. H., İnanır, S., Çöpoğlu, Ü. S., & Erbaş, O. (2014) · PubMed Central · Cited by 14
Kamal, M. J., Wang, X. S., Shi, Q., Mendoza, T. R., García-González, A., Bokhari, R. H., Cleeland, C. S., & Fogelman, D. R. (2020) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2020.01.007 · Cited by 14
Adraoui, F. W., Douw, L., Martens, G. J. M., & Maas, D. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097680 · Cited by 14
Besedovsky, L., Schmidt, E.-M., Linz, B., Diekelmann, S., Lange, T., & Jan Born, A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116658991 · Cited by 16
Ballenger, J. C. (2011) · Yearbook of Psychiatry and Applied Mental Health · doi:10.1016/s0084-3970(10)79430-5 · Cited by 14
Drugs with glutamate-based mechanisms of action in psychiatry
Chrobak, A., & Siwek, M. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00656-8 · Cited by 11
Treatment-refractory schizophrenia: what is it and what has been done about it?
Citrome, L. (2011) · Neuropsychiatry · doi:10.2217/npy.11.35 · Cited by 13
Ito, N., Sasaki, K., Takemoto, H., Kobayashi, Y., Isoda, H., & Odaguchi, H. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.07.023 · Cited by 12
Pharmacotherapy of schizophrenia: immunological aspects and potential role of immunotherapy
Chauhan, P., Kaur, G., Prasad, R., & Singh, H. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2021.1994857 · Cited by 12
Mayeli, A., Clancy, K. J., Sonnenschein, S. F., Sarpal, D. K., & Ferrarelli, F. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114926 · Cited by 12
Minocycline as a treatment for schizophrenia: is the discussion truly finished?
Kishimoto, T., Horigome, T., & Takamiya, A. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(18)30389-4 · Cited by 12
Seitz‐Holland, J., Alemán‐Gómez, Y., Cho, K. I. K., Pasternak, O., Cleusix, M., Jenni, R., Baumann, P., Klauser, P., Conus, P., Hagmann, P., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01814-5 · Cited by 12
Liang, J., Guan, X., Sun, Q., Hao, Y., & Xiu, M. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111092 · Cited by 11
Mehrotra, S., Pecaut, M. J., & Gridley, D. S. (2014) · PubMed · Cited by 11
Do patterns of synaptic pruning underlie psychoses, autism and ADHD?
de Silva, P. N. (2018) · BJPsych Advances · doi:10.1192/bja.2017.27 · Cited by 14
Li, X., Wang, X., Yang, Y., Zhou, J., Wu, X., Zhao, J., Zhang, J., Guo, X., Shao, M., Song, M., et al. (2024) · Schizophrenia · doi:10.1038/s41537-024-00494-w · Cited by 10
IUPHAR review – Novel therapeutic targets for schizophrenia treatment: A translational perspective
Begni, V., Marchesin, A., & Riva, M. A. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107690 · Cited by 10
Alavi, S., Darharaj, M., Bilehsavar, S. H., Amini, M., Zafarghandi, M. B. S., Berenji, V., & Arezoomandan, R. (2021) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000460 · Cited by 10
Six Decades of Dopamine Hypothesis: Is Aryl Hydrocarbon Receptor the New D2?
Sfera, A. (2023) · Reports — Medical Cases Images and Videos · doi:10.3390/reports6030036 · Cited by 10
Wei, Y., Xu, X., Guo, Q., Zhao, S., Qiu, Y., Wang, D., Yu, W., Liu, Y., & Wang, K. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.11.024 · Cited by 9
Meloni, A., Paribello, P., Pinna, M., Contu, M., Ardau, R., Chillotti, C., Congiu, D., Gennarelli, M., Minelli, A., Buson, L., et al. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.10.012 · Cited by 9
Zapata, R. C., Rosenthal, S. B., Fisch, K. M., Dao, K., Jain, M., & Osborn, O. (2020) · Scientific Reports · doi:10.1038/s41598-020-75624-2 · Cited by 9
Roméo, B., Lestra, V., Martelli, C., Amirouche, A., Benyamina, A., & Hamdani, N. (2023) · Acta Neuropsychiatrica · doi:10.1017/neu.2023.24 · Cited by 9
Inflammation and Schizophrenia
Bowcut, J., & Weiser, M. (2018) · Psychiatric Annals · doi:10.3928/00485713-20180416-01 · Cited by 9
Minocycline as adjunct therapy for a male patient with deficit schizophrenia
Chen, X., Xiong, Z., Li, Z., Yang, Y., Zheng, Z., Li, Y., Xie, Y., & Li, Z. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s179658 · Cited by 9
The Role of Inflammation and the Immune System in Schizophrenia
Müller, N., Weidinger, E., Leitner, B., & Schwarz, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801829-3.00019-7 · Cited by 10
Treating psychiatric symptoms and disorders with non-psychotropic medications
Hede, V., & Devillé, C. (2019) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2019.21.2/vhede · Cited by 8
Li, M., Luo, G., Qiu, Y., Zhang, X., Sun, X., Li, Y., Zhao, Y., Sun, W., Yang, S., & Li, J. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01650-6 · Cited by 8
Venkatasubramanian, G., & Debnath, M. (2014) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2014.12.1.8 · Cited by 10
Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT
Deakin, J. F. W., John Suckling, A., Dazzan, P., Joyce, E. M., Lawrie, S. M., Upthegrove, R., Husain, N., Chaudhry, I. B., Dunn, G., Jones, P. B., et al. (2019) · Efficacy and Mechanism Evaluation · doi:10.3310/eme06070 · Cited by 8
Kajero, J. A., Seedat, S., OHAERI, J. U., Akindele, A. J., & Aina, O. O. (2022) · Scientific Reports · doi:10.1038/s41598-022-24235-0 · Cited by 8
Pharmacological management of neurocognitive impairment in schizophrenia: A narrative review
Arsenault‐Mehta, K., Hochman‐Bérard, M., Johnson, A., Semenova, D., Nguyen, B., Willis, J. V., Mouravska, N., Joober, R., & Zhand, N. (2023) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12382 · Cited by 8
Lisiecka, D. M., John Suckling, A., Barnes, T. R. E., Chaudhry, I. B., Dazzan, P., Husain, N., Jones, P. B., Joyce, E. M., Lawrie, S. M., Upthegrove, R., et al. (2015) · Trials · doi:10.1186/s13063-015-0580-x · Cited by 8
Cognitive neurosciences: A new paradigm in management and outcome of schizophrenia
Shrivastava, A., & Johnston, M. (2010) · Indian Journal of Psychiatry · doi:10.4103/0019-5545.64575 · Cited by 9
Synthesis and biological evaluation of novel flavanone derivatives as potential antipsychotic agents
Gu, H.-S., Chen, X., Zhang, J., Zhang, L., & Li, L. (2016) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12843 · Cited by 8
Minocycline for Schizophrenia: A critical review
Miyaoka, T. (2012) · Open Journal of Psychiatry · doi:10.4236/ojpsych.2012.224056 · Cited by 8
Schizophrenia and Related Psychoses
(2021) · Wiley eBooks · doi:10.1002/9781119870203.mpg001 · Cited by 9
Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Bumb, J. M., Enning, F., & Leweke, F. M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660165 · Cited by 7
The Importance of Glia in Dealing with Stress
Woodbury-Fariña, M. A. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.08.003 · Cited by 7
Metadata
- Authors
- Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S.
- Affiliations
- Shalvata Mental Health Center (IL)
- Corresponding author
- Levkovitz, Yechiel
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2009-11-03
- Volume
- 71
- Issue
- 02
- Pages
- 138-149
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2084588595
- Cited by
- 387
- References
- 112
- Citations by year
- 2026: 2 · 2025: 11 · 2024: 10 · 2023: 17 · 2022: 16 · 2021: 23 · 2020: 26 · 2019: 22 · 2018: 26 · 2017: 15 · 2016: 33 · 2015: 42 · 2014: 34 · 2013: 44 · 2012: 27
- FWCI
- 13.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- minocycline, early-phase schizophrenia, negative symptoms, cognitive impairment, executive function, adjunctive therapy, glutamatergic system, nitric oxide synthase inhibition, microglial activation, atypical antipsychotics, Scale for the Assessment of Negative Symptoms
- MeSH terms
- Adolescent, Adult, Cognition, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Male, Minocycline, Placebos, Psychiatric Status Rating Scales, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
